Bob Ingram (HBM Healthcare Investments)
September 29, 2020 11:25 AM EDTUpdated 01:59 PM
People

Black Di­a­mond brings in ex-GSK CEO Bob In­gram to chart new path in pre­ci­sion on­col­o­gy

Nicole DeFeudis

Editor

Black Di­a­mond Ther­a­peu­tics start­ed the year with a more than $200 mil­lion vault on­to Nas­daq and a clin­ic-bound al­losteric ther­a­py — and now, the young …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

A service from the Financial Times